Dimerix Limited (AU:DXB) has released an update.
Dimerix Limited’s CEO, Dr. Nina Webster, delivered a keynote speech at the 7th Annual Bio Connections Australia, focusing on the Australian biotech industry’s success strategies in relation to Dimerix’s clinical development and licensing deals. The company, which is advancing a Phase 3 clinical study for its leading drug candidate DMX200 for FSGS, a rare kidney disease, aims to transform medical research into commercial products, with no current approved drugs for FSGS worldwide.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.
